DiaMedica Therapeutics (OTCMKTS:DMCAF) vs. Tricida (NASDAQ:TCDA) Critical Survey

Tricida (NASDAQ:TCDAGet Rating) and DiaMedica Therapeutics (OTCMKTS:DMCAFGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Tricida and DiaMedica Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tricida N/A N/A -$176.57 million ($3.44) -3.09
DiaMedica Therapeutics N/A N/A -$2.22 million N/A N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Tricida and DiaMedica Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tricida 0 1 2 0 2.67
DiaMedica Therapeutics 0 0 0 0 N/A

Tricida presently has a consensus target price of $16.67, indicating a potential upside of 56.94%. Given Tricida’s higher probable upside, research analysts plainly believe Tricida is more favorable than DiaMedica Therapeutics.


This table compares Tricida and DiaMedica Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tricida N/A -716.22% -92.54%
DiaMedica Therapeutics N/A N/A N/A

Risk & Volatility

Tricida has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Institutional and Insider Ownership

88.5% of Tricida shares are held by institutional investors. 70.4% of Tricida shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Tricida beats DiaMedica Therapeutics on 5 of the 8 factors compared between the two stocks.

About Tricida (Get Rating)

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

About DiaMedica Therapeutics (Get Rating)

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.